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Seeing Spirals*
Nathaniel Reichek, MD†‡
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fiIn this issue of iJACC, Florian et al. (1), using
cardiac magnetic resonance (CMR), describe a
previously unrecognized—or at least unnamed—3-
dimensional spiral pattern of myocardial hypertro-
phy in a population of 132 Belgian and Italian
patients with hypertrophic cardiomyopathy (HCM).
In a large majority (86%) of the population studied,
myocardial hypertrophy extended in a counter-
clockwise spiral from the basal anterior septum
toward the apex of the left ventricle. Subjects with
greater spiral rotation or extent of hypertrophy were
older and more likely to have obstructive physiol-
ogy, hypertension, and higher left ventricular mass.
See page 702
Conversely, the prevalence of myocardial fibrosis on
delayed enhancement imaging, an adverse prognostic
sign in HCM, was somewhat lower in those with than in
those without a spiral distribution of hypertrophy.
It is genuinely surprising to see a new interpretation
of the geometry of hypertrophy in HCM emerge at
this late date. After all, noninvasive cardiac imaging
was first applied to HCM some 43 years ago. One of
the ancients in the field, I was in the audience when
Pravin Shah first described systolic anterior motion of
the anterior mitral leaflet on M-mode echocardiogra-
phy at the American College of Cardiology annual
meeting in 1968 (2). Comically, the next speaker on
the new method of echocardiography, who shall go
unnamed, described the “pathognomonic” mitral valve
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ortic stenosis in diastole (!). Over the ensuing years,
ssessment of myocardial hypertrophy by echo and
linical recognition of HCM itself blossomed, thanks
n good part to echocardiography. At the National
nstitutes of Health, the convergence of the large
CM program originally initiated under Dr. Braun-
ald’s leadership, development of the septal myomec-
omy procedure by Glenn Morrow, and Walt Henry’s
arly contributions using echocardiography were fol-
owed by Barry Maron’s larger, longer, and more
ystematic studies of HCM over many decades (3-6).
he work of these investigators and many others led
ver time to an extensive and seemingly mature and
efinitive literature on the relationship between echo
ndings of hypertrophy, clinical manifestations, prog-
osis, and management. Beginning in 1989, the im-
act of genetic studies by the Seidmans, and subse-
uently also by Roberts, Marian and others, shed
undamental new light on the molecular basis of the
isease, its heterogeneity and genotype-phenotype
elationships (7–9).
Application of CMR to HCM began in the mid
980s, early on in the development of the field (10).
arly studies demonstrated the incremental value of
MR in evaluation of ventricular structure in
CM and were followed by some of the earliest
tudies of the effects of disease on myocardial strain
n man (11). But it is only in recent years that CMR
as become an essential tool in the clinical evalua-
ion of HCM, providing unique information (12–16).
he impact of CMR has been greatest in demon-
trating the presence and adverse correlates of
yocardial fibrosis in HCM, using the CMR de-
ayed enhancement technique. Soon, we can expect
hat newer methods that can detect microscopic
nterstitial fibrosis, as opposed to the grossly visible
brosis, both with high and with intermediate
ignal intensity, seen with conventional delayed
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713enhancement, will extend our understanding of the
role of fibrosis in HCM. However, the contribu-
tions of CMR have also included more comprehen-
sive assessment of the disorder, including segmental
distribution of hypertrophy, which has led to more
consistent recognition of the apical variant of HCM
as one result; improved quantitation of left ventric-
ular mass, leading to recognition of the contribution
of global hypertrophy to prognosis; quantitative
studies of regional myocardial perfusion and its
relationship to wall thickness and presence or ab-
sence of fibrosis; and new insights into the associ-
ation of mitral leaflet anatomic abnormalities with
HCM and their contribution to idiopathic hyper-
trophic subaortic stenosis pathophysiology.
But considering all of the studies of HCM
patients over the years, to realize that a finding such
as spiral hypertrophy, so obvious once recognized,
had been overlooked is really quite extraordinary.
More importantly, one must ask, are the authors
right? And if they are, what does this finding mean?
The validity of the observation is a bit harder to
judge than one might suppose, since the methods
used, detailed in an online supplement rather than
the body of the paper itself, are not the conventional
clinical methods for left ventricular wall thickness
measurement. Nonetheless, they seem quite appro-
priate, and the concept passes the “eyeball” test
when one reviews the images published and re-
reviews one’s own CMR cases. Nonetheless, formal
confirmation from other laboratories and different
HCM populations with a wide range of genetic
patterns would be most helpful.
As to the significance of the finding, that remainsidiopathic hypertrophic subaortic ste-
gene missense mu
62:999–1006.atic genetic studies, major clinical correlates, or
outcome data. One would hope that HCM inves-
tigators worldwide would turn their attention to
this question. In particular, the Marons and their
colleagues, as well as the National Heart, Lung, and
Blood Institute’s CMR group led by Andrew Arai,
may have much to contribute. There are some
obvious questions to be addressed. First, are there
specific genotypes that are associated with the spiral
HCM pattern? Second, if myocardial fibrosis is less
in the spiral group, are adverse outcomes also less
prevalent, since fibrosis appears to be associated
with adverse outcomes? Finally, how does the spiral
HCM pattern relate to the extensively studied
changes in myocardial mechanics that occur in
HCM, with reductions in strain, changes in cir-
cumferential/longitudinal strain ratios, and in-
creases and shifts in long-axis positioning of twist?
The spiral pattern looks tailor-made to affect twist.
But since the spiral of hypertrophied myocardium
would be shortening in a direction opposite the
counterclockwise apical rotation that results from
twist, the implication is that the hypertrophied
tissue may actually be weaker and shorten less than
thinner portions of the HCM ventricle and that any
increase in twist may be attributable to that weak-
ness. The next few years should be an interesting
time for seeing spirals.
Reprint requests and correspondence: Dr. Nathaniel
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